

Stephen J Atkinson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8921869/publications.pdf>

Version: 2024-02-01

13
papers

1,144
citations

759233

12
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

1859
citing authors

#	ARTICLE	IF	CITATIONS
1	Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2262-2287.	6.4	14
2	Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3249-3281.	6.4	19
3	Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10806-10833.	6.4	31
4	Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10711-10741.	6.4	17
5	Identification of a Series of <i>N</i> -Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10742-10771.	6.4	14
6	Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10772-10805.	6.4	17
7	Design and Synthesis of a Highly Selective and <i>In Vivo</i> -Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9070-9092.	6.4	40
8	The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9093-9126.	6.4	41
9	Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. <i>Science</i> , 2020, 368, 387-394.	12.6	274
10	GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1581-1587.	2.8	25
11	Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5212-5241.	6.4	14
12	Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4317-4334.	6.4	94
13	Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. <i>Nature Chemical Biology</i> , 2015, 11, 189-191.	8.0	544